TP53 and neoplasm: Recent genomic studies and GEM models have indeed highlighted that alterations (mutations, deletions) in TP53, PTEN, and RB1 tumor suppressor genes are major co-operating events that facilitate resistance to ADT and next-generation anti-androgen therapies through an NED process associated with rapid metastatic progression and decreased overall survival29,37–39.